FDA OK for LVAS (left ventricular assist system) enhancement boosts World Heart's shares
This article was originally published in Clinica
Executive Summary
World Heart's shares soared earlier this week, almost doubling in value, after the US FDA cleared for sale a key component that may reduce the incidence of strokes associated with its left ventricular assist system (LVAS).